IMPORTANT PRESENTATION Rescheduled for May 11th
ORA Noon Conference offered via Zoom
SAVE THE DATE! May 11, 2021 at 1:00 pm
Topic: Writing NIH Other Support Pages
Requires Changes as of January 25, 2022
Please register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.
OUHSC will start implementing this process on July 1, 2021.
OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (email@example.com) or Darrin Akins (firstname.lastname@example.org).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Reckitt is seeking to engage with academic partners to 1) develop approaches to enhance oral drug delivery into the pharyngeal, esophageal, or colon; 2) enhance the safety of OTC medications, or 3) develop natural/non-medicated solutions for upper and lower GI conditions, sore throat, cough, cold, flu, and pain. Submission entails a 1-pg non-confidential summary of technology (deadline 5/27/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies. Proposal template available upon request (submission deadline 6/18/21).
Reopening of Research at OUHSC
The Phase Two Return to Research Plan has allowed for the successful, gradual, and phased reopening of bench laboratory research. One key component of Phase Two was the population density limit of one researcher for every 250 sq ft of laboratory space. This conservative population density was established to minimize COVID-19 risk in the research environment while the Vice President for Research (VPR) office evaluated the effectiveness of the reopening plan. Based upon that review and the current COVID-19 guidance and data, the VPR office, in consultation with the Specific Pathogens Preparedness Operations/Emergency Operations Exec team, has determined that effective Tuesday, June 1, bench laboratory research areas may increase capacity to the extent that allows a 3-foot social between all personnel. In accordance with campus COVID-19 policies, masks must be worn at all times in indoor facilities, including labs. If you are uncertain whether your lab can accommodate your personnel numbers observing the required 3-foot social distancing requirement, please contact Chris Tucker in Operations to request your space be measured for this new COVID capacity. Also in accordance with campus policy, labs remain closed to K-12 students but open to undergraduates, graduates, and post-docs from any institution, provided the following are observed:
- non-HSC individuals will complete the online visitor screening tool prior to their first day on campus
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will strongly encouraged to be vaccinated against COVID-19
- all individuals will be informed that they must comply with the HSC COVID-19 Response Plan
With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify any gaps that this leaves, please email email@example.com. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan.
UPDATE: HSC COVID-19 Response Plan - effective April 13, 2021
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Section I Telecommuting – Telecommuting in response to COVID-19 is being phased out.
- By June 2, 2021, at least 50% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By July 1, 2021, at least 75% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By August 1, 2021, 100% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus
Section III Social Distancing and Gatherings – Effective June 1, social distance measurement will be 3 feet, except in patient care and eating areas which remain at 6 feet.
-This information is included in the Response Plan now for planning purposes. Our medical and public health experts are hopeful that more students and employees will be able to complete their vaccine series in the next few weeks.
-The 6-foot requirement remains in effect until June 1. Operations will replace signs at that time.
Section V Cleaning Facilities and Equipment – Updated to reflect changes to cleaning protocols in response to recent CDC guidance on cleaning as well as to scientific data regarding COVID-19 surface transmissions. There are also changes to reflect current clinic screening processes (Section VIII) and international travel (Sections VII and IX), as well as a number of non-substantive changes made for clarification. Please ensure your area’s Return to Service Plans are updated to reflect these changes.
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain these are current and are posted on the lab door and inside the laboratory.
- Familiarize yourself with OU Health Sciences Center COVID-19 Resources
- Follow all masking and social distancing guidelines as described in the OUHSC COVID-19 Return Plan
- Wash your hands often.
- It’s a good practice to follow the HSC’s COVID-19 protocols even when you are home or in the community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Notice to Extend PA-18-795 (NOT-HS-21-012)
Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Advance Health Equity (NOT-HS-21-014)
Implementation of Changes to the Biographical Sketch and Other Support Format Page (NOT-OD-21-110)
Guidance Regarding Reduction of Effort for Surgeons on NIA Individual Mentored K Awards
Pre-Application Webinar for RFA-CA-21-029, Centers for Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required) (NOT-CA-21-073)
Notice of Extension of the Expiration Date of PAR-19-159, "Bioengineering Research Grants (BRG)(R01 Clinical Trial Required)" (NOT-EB-21-012)
Notice of Information: Change in NCATS Prior Approval Process for New CTSA Program Pilot Projects and KL2 Projects that Involve Human Subjects Research (NOT-TR-21-026)
Request for Information: Response to Proposed NIH Sleep Disorders Research Plan Critical Opportunities and Strategic Goals (NOT-HL-21-011)
Notice of Change: Extension for PAR-18-820, "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)"(NOT-AG-21-022)
Notice of Change in Key Dates for RFA-AI-20-078, Immune Development in Early Life (IDEaL)(U19 Clinical Trial Not Allowed) (NOT-AI-21-049)
Notice of NICHD Participation in RFA-AI-20-077 Immune Development in Early Life (IDEaL)(U01 Clinical Trial Not Allowed) (NOT-HD-21-031)
Notice to Extend PA-18-794 (NOT-HS-21-013)
Notice of Modification for RFA-MD-21-007, Centers for Multiple Chronic Diseases Associated with Health Disparities:Prevention, Treatment, and Management (P50 Clinical Trial Required) (NOT-MD-21-019)
Temporary Extension of Eligibility for the NINDS F32 Award Due the COVID-19 Pandemic
Notice of Intent to Publish a Funding Opportunity Announcement for Acquired Resistance to Therapy Network (ARTNet)(U54 Clinical Trial Not Allowed) (NOT-CA-21-063)
Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet) (U24 Clinical Trial Not Allowed)
Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Cell Atlas Network (BICAN): Comprehensive Center on Human and Non-human Primate Brain Cell Atlases (UM1 Clinical Trial Not Allowed)(NOT-MH-21-260)
Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (U01 Clinical Trial Not Allowed)(NOT-MH-21-261)
Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Cell Atlas Network (BICAN):Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE) (U24 Clinical Trial Not Allowed) (NOT-MH-21-262)
Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants (NOT-CA-21-070)
Notice of Special Interest (NOSI): Expanding Cancer Control Research in Persistent Poverty Areas
Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder (NOT-DA-21-003)
Notice of Special Interest (NOSI): Leveraging Transformative Connectome Resources in Model Organisms to Elucidate the Neurobiology of Substance Use Disorders (NOT-DA-21-006)
FDA Notice of Special Interest (NOSI) to Add COVID-19 Capacity Building Grants to PAR-18-604 Vet-LIRN Network Capacity-Building Projects (Vet-LIRN) (NOT-FD-21-014)
Notice of Special Interest (NOSI): Reproductive Health, Pregnancy, and Parenting among Women with Disabilities(NOT-HD-21-025)
Notice of Special Interest (NOSI): Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth (NOT-HD-21-026)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)(PAR-21-225) - Deadline September 5, 2021
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)(PAR-21-226) - Deadline September 5, 2021
Resource Center for the Support for Research Excellence (SuRE) Program (U24 - Clinical Trial Not Allowed) (PAR-21-227) Deadline September 24, 2021
Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed)(RFA-AI-21-017) – Deadline September 8, 2021
Mobile Health Solutions to Rectify Digital Inequality in Communities Affected by Drug Addiction (R43/R44 Clinical Trial Optional)(RFA-DA-22-001) – Deadline August 13, 2021
Addressing Social Determinants of Health to Eliminate Oral Health Disparities (UG3/UH3 Clinical Trials Optional)(RFA-DE-22-002) - Deadline July 08, 2021
NIDDK Short-Term Research Experience Program to Unlock Potential (STEP-UP) (R25 Clinical Trial Not Allowed)(RFA-DK-21-023) - Deadline September 1, 2021
Pediatric and Perinatal COVID-19 Registry (U18) Clinical Trials Optional (RFA-FD-21-035) -Deadline July 6, 2021
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain(R01 Clinical Trial Not Allowed) (RFA-MH-21-175) – Deadline October 8, 2021 and October 7, 2022
Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) (RFA-NS-21-021) – Deadline July 1, 2021 and October 20, 2021
Translational Neural Devices (U44 Clinical Trial Optional) (RFA-NS-21-022) – Deadline July 1, 2021 and October 20, 2021
NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) (RFA-RM-21-018) – Deadline September 03, 2021
OTHER FEDERAL DEADLINES
Administration for Community Living – Innovations in Nutrition Programs and Services-Community Research – Deadline May 24, 2021
Department of Defense (DOD) – Neurofibromatosis Research Program (NFRP) – Clinical Trial Award – Required PreApplication due July 8, 2021
DOD – NFRP – Early Investigator Research Award – Required PreApplication due July 8, 2021
DOD – NFRP – Exploration-Hypothesis Development Award – Required PreApplication due July 8, 2021
DOD – NFRP – Investigator-Initiated Research Award – Required PreApplication due July 8, 2021
DOD – NFRP – New Investigator Award – Required PreApplication due July 8, 2021
DOD – NFRP – Synergistic Idea Award – Required PreApplication due July 8, 2021
Substance Abuse and Mental Health Services Administration (SAMHSA) – First Responders Comprehensive Addiction and Recovery Act Grant – Deadline May 17, 2021
SAMHSA – Community Mental Health Centers Grant Program – Deadline May 21, 2021
US Department of Agriculture (USDA) – Distance Learning and Telemedicine Grants – Deadline June 4, 2021
USDA – Rural Business Development Grant – Deadline Ongoing
American Psychiatric Association Foundation – Helping Hands Grant - Deadline May 31, 2021
Helmsley Charitable Trust – Type I Diabetes (TID) Program – Concept Paper June 11, 2021
Please see attached documents.